June 08, 2017 | In January 2016, one clinical trial volunteer in France died, four others were hospitalized, and two of those went on to have long-term neurological damage. Attempting to provide answers to what went wrong, a study published in Science now reports that the drug candidate responsible for the tragedy, BIA 10-2474, covalently binds several enzymes in addition to the fatty acid amide hydrolase (FAAH) it was designed to block. Chemical & Engineering News